KKR sells Capsugel for USD5.5 billion, shares funds to staff

Royal Dutch Shell

KKR said it has sold Capsugel to Lonza for USD $5.5 billion after the group received regulatory approvals to sell the dosage forms company.

The company said as part of the sale, approximately $35 million of proceeds were distributed to non-management level employees of the company, including all colleagues from the company’s thirteen manufacturing facilities around the world. All Capsugel employees globally participated in the distribution of proceeds from the sale.

“Capsugel was a terrific outcome, not only in terms of the financial results for our fund investors, but also in the way we and the management team and all of the company’s employees partnered together to really drive a transformation of the company,” said Pete Stavros, Member of KKR and Head of KKR’s Industrial investment team. “In our industrial manufacturing companies, we have endeavored to give everyone an opportunity to participate in the benefits of ownership of their business as we believe it drives a higher level of engagement which can drive break out results. Capsugel is a great example of that.”

KKR has utilized this unique employee participation model at three other industrial companies: Capital Safety, Gardner Denver and C.H.I. Overhead Doors. Beyond extending this participation to all employees at these businesses, KKR also expanded employee engagement by having companies invest in the workforce in areas such as safety and health, and by partnering with the workforce to give back to their communities.